Roche\'s Tecentriq combo recommended in Europe for nonsmall cell lung cancer

Roche's Tecentriq combo recommended in Europe for non-small cell lung cancer

06:11 EDT 29 Jul 2019 | Pharmafile

Riche’s blockbuster immunotherapy Tecentriq (atezolizumab) is closing in on securing yet another approval after it revealed that the drug was awarded a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).

The recommendation covers Tecentriq’s use in combination with carboplatin and Abraxane chemotherapy in the first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adult patients whose tumours are not EGFR mutant or ALK-positive.

Roche\'s Tecentriq combo recommended in Europe for nonsmall cell lung cancer

Roche's Tecentriq combo recommended in Europe for non-small cell lung cancer

Riche’s blockbuster immunotherapy Tecentriq (atezolizumab) is closing in on securing yet another approval after it revealed that the drug was awarded a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).

More From BioPortfolio on "Roche's Tecentriq combo recommended in Europe for non-small cell lung cancer"